Pediatric Brain Tumor Market

Market Overview:

The pediatric brain tumor market is growing at a CAGR of 6.8% over the forecast period and is expected to reach USD 1,843.7 million by 2022-2030. Pediatric brain tumor is an uncontrolled or abnormal growth of normal cells in the brain in children. Brain tumors are mainly of two types, cancerous (malignant) and non-cancerous (benign). It is the second most common type of cancer in children and accounts for about 25% of childhood cancers. Pediatrictumor cases are increasing globally, driving the growth of the market. Advanced diagnostic technology and new treatments are also major market drivers. Growing healthcare infrastructure, extensive insurance coverage, government initiatives and emerging economies are driving the market. Rising R&D and clinical trial funding along with FDA approvals are also major growth factors for the global pediatric brain tumor market.

Market Dynamics

The pediatric brain tumor market is influenced by several dynamics. Firstly, the high unmet medical need drives research and development efforts to discover innovative therapies. Advances in genomic profiling and personalized medicine contribute to targeted treatment approaches. Additionally, collaborations between academic institutions, pharmaceutical companies, and government organizations facilitate knowledge sharing and accelerate drug development. Regulatory incentives, such as orphan drug designation and pediatric exclusivity, encourage investment in pediatric brain tumor therapies. Furthermore, public awareness campaigns and advocacy groups play a crucial role in raising funds, supporting research, and improving access to care. These dynamics collectively shape the landscape of the pediatric brain tumor market.


Several drivers contribute to the growth and advancement of the pediatric brain tumor market. Firstly, increased understanding of the molecular and genetic basis of brain tumors drives the development of targeted therapies. Advances in diagnostic techniques, such as imaging technologies and liquid biopsies, enable early detection and precise monitoring of tumor progression. Supportive regulatory policies and incentives encourage pharmaceutical companies to invest in pediatric oncology research and development. Additionally, growing public awareness, advocacy efforts, and fundraising initiatives contribute to increased funding for pediatric brain tumor research. Collaborations between academic institutions, healthcare providers, and industry stakeholders also drive innovation and accelerate the development of novel treatments.

Market resistant

While the pediatric brain tumor market is driven by various factors, there are also certain challenges and resistance that can impact its growth. These include the complexity and heterogeneity of brain tumors, limited availability of effective treatments, high costs of research and development, and regulatory hurdles associated with pediatric clinical trials.

Market Segmentation:

The global pediatric brain tumor market has been segmented on the basis of types including gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papillomas/carcinomas, non-neuroepithelial tissue tumors, meningeal tumors and others . Gliomas are further sub-segmented into astrocytoma, malignant gliomas and others. Mixed neuronal-glial tumors are further sub-segmented into gangliogliomas, subependymal giant cell tumors, pleomorphic xanthoastrocytomas and others. Embryonic tumors are further sub-segmented into primary neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor and others. Tumors arising from non-neuroepithelial tissues are further sub-segmented into craniopharyngiomas, pineal region tumors and others. On the basis of diagnosis, the pediatric brain tumor market is segmented into physical examination, imaging tests, brain or spinal tumor biopsy, lumbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Angiography and others. Magnetic Resonance Imaging (MRI) is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Infusion, Functional MRI (fMRI) and others. Brain tumor or spinal cord biopsy is further sub-segmented into stereotactic needle biopsy, craniotomy and others.

On the basis of treatment, the pediatric brain tumor market has been segmented into surgery, therapies, drug treatment and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), shunt placement/revision and others. The therapies include radiation therapy, chemotherapy, targeted therapy, and others. Chemotherapy includes carboplatin, carmustine (BCNU), cisplatin, cyclophosphamide, etoposide, lomustine (CCNU), methotrexate, temozolomide, thiotepa, vincristine and others. Drug therapy is further sub-segmented into corticosteroids, antiepileptics (antiepileptics), hormones, and others. On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes and others. 

Market Barriers

The pediatric brain tumor market faces several barriers. Limited research funding, regulatory challenges in conducting clinical trials, and the lack of reliable biomarkers and diagnostic tools are key obstacles. Additionally, the complexity and heterogeneity of brain tumors make developing effective treatments challenging. The rarity of pediatric brain tumors and the need for specialized expertise and infrastructure further impede progress. The high costs associated with research and development, coupled with the small patient population, can also hinder investment and the availability of affordable therapies. Overcoming these barriers is essential to advance treatment options and improve outcomes for pediatric brain tumor patients.

Post COVID Impact

The pediatric brain tumor market encompasses the research, development, and commercialization of therapies for pediatric patients with brain tumors. Pre-COVID, the market faced barriers such as limited research funding, regulatory challenges, and the complexity of brain tumors. Post-COVID, the pandemic has impacted various aspects of the market, including disruptions in clinical trials, delayed diagnoses, and changes in healthcare priorities. The pandemic's long-term effects on funding, research, and patient care are yet to be fully understood. However, increased focus on telemedicine and digital health solutions may present new opportunities for remote monitoring and patient support in the pediatric brain tumor market.

Market Trends

Several trends are shaping the pediatric brain tumor market. Firstly, there is an increasing focus on personalized medicine, with a growing emphasis on genomic profiling and targeted therapies. Secondly, immunotherapy approaches, including CAR-T cell therapy, are being explored for pediatric brain tumor treatment. Additionally, advancements in imaging technologies and liquid biopsies are improving diagnostic accuracy and monitoring of treatment response. Collaborative efforts between research institutions and pharmaceutical companies are driving innovation and clinical trial initiatives. Furthermore, there is a rising awareness of the long-term effects of treatments, leading to a greater emphasis on survivorship care and supportive services for pediatric brain tumor patients.

Market Challenges

Limited Treatment Options: Pediatric brain tumors are complex and diverse, with different types and subtypes. However, the availability of specific treatment options for each subtype is limited, resulting in a lack of tailored therapies. This limits the ability to achieve optimal outcomes for patients.

Heterogeneity of Tumors: Pediatric brain tumors exhibit significant heterogeneity, both within and between patients. This makes it challenging to develop standardized treatment approaches and identify effective biomarkers for diagnosis, prognosis, and treatment response.

Lack of Pediatric-Specific Clinical Trials: Clinical trials specifically designed for pediatric brain tumor patients are relatively rare. This is due to the smaller patient population, ethical considerations, and regulatory challenges. As a result, treatment decisions are often based on extrapolation from adult studies, leading to potential gaps in safety and efficacy data.

Long-Term Side Effects: Pediatric brain tumor treatments can cause long-term side effects, such as cognitive impairments, developmental delays, and endocrine disorders. Addressing and minimizing these side effects require comprehensive survivorship care programs, which may not always be readily available or accessible.

Cost and Reimbursement Challenges: Developing therapies for pediatric brain tumors involves substantial research and development costs. The small patient population and the need for specialized pediatric expertise further complicate cost considerations. Additionally, reimbursement challenges may limit the availability and affordability of innovative treatments.

Key Developments

Targeted Therapies: Advances in molecular profiling and understanding of genetic alterations have led to the development of targeted therapies for specific types of pediatric brain tumors. Drugs like dabrafenib and trametinib have shown promising results in treating pediatric patients with BRAF V600-mutant brain tumors.

Immunotherapy: Immunotherapy approaches, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in the treatment of pediatric brain tumors. CAR-T therapies like Kymriah (tisagenlecleucel) and Yescarta (axicabtageneciloleucel) have received FDA approval for the treatment of certain types of pediatricleukemias, and their use is being explored in brain tumor patients as well.

Liquid Biopsies: Liquid biopsies, which involve the analysis of tumor-specific DNA or RNA fragments present in bodily fluids like blood, cerebrospinal fluid, or urine, are emerging as a non-invasive tool for diagnosing and monitoring pediatric brain tumors. These tests have the potential to provide real-time information about tumor mutations and treatment response.

Collaborative Efforts: Collaborations among research institutions, pharmaceutical companies, and advocacy groups have strengthened research and development efforts in pediatric brain tumor treatments. Initiatives like the Pediatric Brain Tumor Consortium (PBTC) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) bring together experts to conduct clinical trials, share data, and advance the field collectively.

Precision Medicine: The application of precision medicine approaches, such as genomic profiling and personalized treatment strategies, is gaining traction in pediatric brain tumor management. Identifying specific molecular targets and tailoring treatment regimens accordingly can potentially improve outcomes and reduce treatment-related toxicities.

Regional Analysis:

Considering the global market scenario, North America holds the largest market share due to various factors such as increasing cases of pediatric brain tumors and related medical complications. Europe is the second largest market where countries like Germany and UK hold the largest market share. In 2014, approximately 10,000 new cases of pediatric brain tumors were observed. New cases of pediatric brain tumors are increasing rapidly in the Asia-Pacific region. Additionally, improving healthcare sector, government initiatives to improve public health and increasing healthcare expenditures are driving the growth of the pediatric brain tumor market in Asia Pacific. Due to low disease knowledge and limited availability of medical facilities, the Middle East and Africa (ME&A) is likely to experience limited market growth. The Global Pharmanucleus Market report includes extensive primary research along with detailed analysis of qualitative and quantitative aspects by various industry experts, key opinion leaders to better understand the market and industry performance . The report provides a clear picture of the current market scenario which includes historical and projected Pediatric Brain Tumor market size in terms of value and volume, technological advancement, macroeconomic factors and guiding in the market. The report provides detailed information and strategies on the main key players in the industry. The report also gives a broad study of different market segments and regions.

Key Players: Some of the key players in this pediatric brain tumor market are: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others

Study objectives of Global Pediatric brain tumor market:

  • To provide a detailed analysis of the structure of the global Pediatric Brain Tumor market with historical and forecast revenue for the next 6 years of the various segments and sub-segments of the market
  • To provide insights into the major drivers, restraints, opportunities, and challenges affecting the growth of the global market
  • To provide market analysis with respect to four major geographies and their countries – Americas, Europe, Asia-Pacific, Middle East and Africa.
  • To provide a detailed analysis of the market segmented by Types, Diagnosis, Treatment, End User and its sub-segments.
  • To provide a detailed analysis of the global Pediatric Brain Tumor market primarily based on value chain analysis, Porter's five forces, price analysis, and supply chain analysis, etc.
  • To provide a detailed country-level market analysis with respect to the current market size and future prospects.
  • Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and global market research and developments
  • To provide an overview of key players and their strategic profiling in the market, thoroughly analyzing their core competencies and drawing a competitive landscape for the Pediatric Brain Tumor market

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!


One of our marquee services We profile relevant start-up companies in the market.


Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.